Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments
Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depressionAdministering drug to mice resulted in an approximately 10% increase in neuron size and densityCybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://ibn.fm/NCORl) — companies…